Brent L. Saunders, Director at ARS Pharmaceuticals, Inc. (SPRY), sold 120,000 shares at $14.25 ($1.7M) on 2025-05-20, disclosed to the SEC on 2025-05-22.
Open-market sale of $1.7M SPRY by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| SKIN | BUY | 2024-08-13 | $44K | — | Filing → |
| BLCO | BUY | 2024-08-07 | $505K | — | Filing → |
| SKIN | BUY | 2023-08-17 | $362K | — | Filing → |